Topics

Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer

15:42 EDT 3 Oct 2019 | OncLive

Durvalumab added to etoposide and platinum-based chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer delays development of new lesions and improves patient-reported outcomes compared with etoposide and platinum-based therapy alone.

Original Article: Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer"

Quick Search

Relevant Topic

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...